KRAS and leukemia: For instance, the most significantly upregulated signatures shared by those leukemia patients are IL-2-STAT5 signaling, inflammation response, angiogenesis, IL-6-JAK-STAT3 signaling, KRAS signaling, allograft rejection and hypoxia, which have been reported in various cancers, indicating these signatures played an important role in cancer progression.